• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Concerta: Brand vs Generic

Concerta: Brand vs Generic

January 1, 2017
Glen Elliott, MD, PhD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Elliott, MD, PhD Editor-in-chief, The Carlat Child Psychiatry Report
In November 2016, the FDA announced that it was requiring two companies to withdraw their generic versions of Concerta (OROS methylphenidate) because of efficacy concerns. Such actions are quite unusual, and when they occur, they tend to shake doctors’ confidence in the generic drug system—which branded drug companies are often eager to encourage. But the Concerta case is hardly an indictment of generic drugs, or even of generic stimulants. Let’s dig a little deeper for some insight into the generic drug process.

Concerta was originally developed and marketed by Janssen Pharmaceuticals (a division of Johnson and Johnson). In 2010, the company lost its marketing exclusivity after its patent expired, and subsequently other companies manufactured generic versions. In approving generic products, the FDA mostly evaluates data showing that the generic formulation is “bioequivalent” to the brand product. This means both that the molecules are identical, and that the rate and extent of drug absorption is not significantly different. The FDA uses the designation “AB” for generics that are bioequivalent to brand, and “BX” for generics that are not equivalent and therefore not substitutable at pharmacies. Sometimes equivalency problems are discovered after a generic drug has been approved (a recent example is bupropion SR).

By 2013, a total of three companies, Actavis, Mallinckrodt, and Kudco, had received FDA approval to sell generic versions of Concerta, with all three generics classified as AB. But in December 2013, the FDA announced that it had received reports of lack of therapeutic effects with generic Concerta pills made by Mallinckrodt and Kudco (not the Actavis version of Concerta, whose bioequivalence has never been questioned). The reports from patients and physicians were specifically about duration of action, with the Mallinckrodt and Kudco products lasting for shorter periods than brand-name Concerta. This should not have been a surprise, because the companies did not have access to the OROS technology that acts as an osmotic pump but rather relied on coated-bead and bilayer technology (the Actavis generic uses the osmotic delivery system).

At the time, the FDA did not take any regulatory action, but said it would monitor and evaluate the issue. However, as more reports validated these concerns, in 2014, the FDA reclassified the Mallinckrodt and Kudco generics to BX, ie, therapeutically nonequivalent. The FDA allowed continued sales of both products, but asked the manufacturers to consider either ­voluntarily withdrawing them from the market or submitting more bioequivalence data. Neither company complied with the FDA’s suggestions, though—in fact, Mallinckrodt instead opted to sue the FDA, a suit that was later dismissed by a Maryland federal judge.

In November 2016, presumably concluding that the companies were being intransigent, the FDA ordered that the two generic products be withdrawn. However, this process may take some time, and we recommend that you specify the manufacturer as Actavis on scripts when you prescribe generic Concerta.

The take-home lesson for the clinician: In the case of Concerta, not all generics are created equal. But we need to be clear that this was not a case of an adulterated or fake product. There were never any safety concerns, and Mallinckrodt and Kudco were selling genuine methylphenidate in a long-acting version—just not as long-acting as Concerta.

For more information, see the FDA’s website at http://www.fda.gov/Drugs/DrugSafety/ucm422569.htm.
Child Psychiatry
KEYWORDS child-psychiatry news_of_note pharmaceutical_industry psychopharmacology
Glen Elliott, MD, PhD

Using Antipsychotics Judiciously in Children

More from this author
www.thecarlatreport.com
Issue Date: January 1, 2017
SUBSCRIBE NOW
Table Of Contents
Evolution of the Autism Diagnosis
Concerta: Brand vs Generic
Internet-Delivered CBT for Adolescents With OCD
Can a 10-Minute Intervention Improve Sleep in Children With ADHD?
From Infantile Autism to Autism Spectrum Disorder
Take The CME Post-Test for Autism in Children and Adolescents, CCPR, January/February 2017
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.